Abstract:Background and Purpose Endomorphins (EMs) have shown great promise as pharmaceutics for the treatment of pain. We have previously confirmed that novel EM analogs CEMR‐1 and CEMR‐2 behaved as potent μ‐opioid receptor agonists and displayed potent antinociceptive activities at the supraspinal and peripheral levels. Herein, the present study was undertaken to evaluate the antinociceptive properties of CEMR‐1 and CEMR‐2 following intrathecal (i.t.) administration. Furthermore, their antinociceptive tolerance and opioid‐like side effects were also determined. Experimental Approach The spinal antinociceptive effects of CEMR‐1 and CEMR‐2 were determined in a series of pain models, including acute radiant heat paw withdrawal test, spared nerve injury (SNI)‐induced neuropathic pain, complete Freund’s adjuvant (CFA)‐induced inflammatory pain, visceral pain and formalin pain. Antinociceptive tolerance was evaluated in radiant heat paw withdrawal test. Key Results Spinal administration of CEMR‐1 and CEMR‐2 produced potent and prolonged antinociceptive effects in acute pain. CEMR‐1 and CEMR‐2 may produce their antinociception through distinct μ‐opioid receptor subtypes. These two analogs also exhibited significant analgesic activities in neuropathic, inflammatory, visceral and formalin pain at the spinal level. It is noteworthy that CEMR‐1 showed non‐tolerance‐forming analgesic properties, and CEMR‐2 exhibited substantially reduced antinociceptive tolerance. Furthermore, both analogs displayed no or reduced side effects on CPP response, physical dependence, locomotor activity and gastrointestinal transit. Conclusions and Implications The present investigation demonstrated that CEMR‐1 and CEMR‐2 displayed potent and long‐lasting antinociception with a favorable side effect profile at the spinal level. Therefore, CEMR‐1 and CEMR‐2 might serve as promising analgesic compounds with minimized opioid‐like side effects.

Novel endomorphin analogs CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favorable side effect profile at the spinal level